Riferimento:
Usoltsev NA, Dhamee MS. usnickolay@gmail.com
Autori:
J Clin Anesth. 2012 Jun;24(4):315-7.
Fonte:
Usoltsev NA, Dhamee MS. usnickolay@gmail.com
Anno:
2012
Azione:
L'acido all-trans retinoico (ATRA) è prescritto a pazienti con leucemia promielocitica acuta. ATRA ha un effetto negativo conosciuto come sindrome da acido retinoico risolvibile dopo la somministrazione di desametasone.
Target:
ATRA/leucemia promielocitica acuta.
ABSTRACT
All-trans retinoic acid (ATRA), a vitamin A derivative, is prescribed for induction of chemotherapy in patients with acute promyelocytic leukemia. Like other chemotherapy agents, ATRA has an adverse effect known as retinoic acid syndrome. The case of a 22 year old woman with acute promyelocytic leukemia, who received ATRA and subsequently developed retinoic acid syndrome, is presented. The patient's symptoms resolved after administration of dexamethasone, allowing the completion of chemotherapy without further complications.
Sostanze: